Zimmer Biomet Holdings (NYSE:ZBH) navigates a tough period with slowing organic revenue growth and analyst downgrades. The company's strategic moves, including salesforce restructuring and autonomous robotics, face scrutiny. BTIG downgraded the stock from Buy to Neutral, removing its $112 price target. The stock trades at $85.50, well below its 52-week high of $108.29.
The Paragon 28 acquisition underperformed, leading to a reduced outlook for its contribution to FY2026. Salesforce restructuring, expected to complete by end of 2027, may cause short-term disruptions. Autonomous robotics commercialization is not expected until late 2027 or early 2028. Despite share buybacks, revenue growth remains challenged amid competition and execution risks.
